Trump Administration to Fast-Track Vape and Nicotine Pouch Approvals, WSJ Reports

The Trump administration is preparing to significantly accelerate the approval process for smoke-free nicotine products such as vapes and oral pouches, The Wall Street Journal reported. The Food and Drug Administration (FDA) is expected to announce the policy shift in the coming days, creating a more streamlined path to market for non-combustible alternatives.

Regulatory Overhaul Details

The reported changes would ease the requirements of the FDA's 2021 premarket review framework. This overhaul aims to simplify the standards for scientific studies and shorten the protracted review times that manufacturers currently face.

Under the existing system, companies have experienced a significant regulatory backlog, leaving many next-generation tobacco products in expensive and lengthy approval cycles. The new rules would establish a more direct regulatory pathway for products like flavored vapes and nicotine pouches.

Market and Industry Impact

A streamlined authorization process is seen as a substantial operational tailwind for major tobacco companies, including Altria Group (MO), Philip Morris International (PM), and British American Tobacco (BTI). For investors, the regulatory easing could signal potential for top-line growth and margin relief as these firms continue their shift from traditional cigarettes to alternative product segments.

Ad

The move comes as the industry has voiced frustration over administrative delays. Altria’s NJOY vape division recently joined other companies in suing the FDA over the bottlenecks. Administration officials reportedly view the new rules as a way to displace a dominant illicit market with regulated, legal alternatives for adult consumers.

Public Health Concerns

The policy shift is expected to face considerable pushback from public health advocates and some bipartisan lawmakers. Critics argue that making it easier to approve flavored products risks increasing youth adoption of nicotine.

These groups maintain that the administration should focus on stricter market enforcement against illegal, unregulated imports rather than lowering the evidentiary standards required for new product approvals.